+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying BL-B01D1, an investigational drug, in patients with metastatic or unresectable non-small cell lung cancer NSCLC and other solid tumors. This Phase 1 trial aims to evaluate the safety, tolerability, pharmacokinetics, and initial effectiveness of BL-B01D1, including determining the best dose and schedule. The study is sponsored by SystImmune Inc. and includes patients with various advanced cancers who have progressed after standard treatments. The study includes two dosing schedules Cohort A receives BL-B01D1 via intravenous infusion on Day 1 and Day 8 every 21 days, while Cohort B receives the drug on Day 1 every 21 days. The trial has three parts dose escalation, dose finding, and dose expansion. Each cohort has different dose groups to identify the maximum tolerated dose and recommended doses for future study phases. Participants will be closely monitored for adverse events, laboratory changes, physical exams, and heart function over one year. Researchers will measure drug levels in the blood and assess tumor response, disease control, and survival outcomes. Participants will have regular visits and assessments to track safety, side effects, physical activity, and overall health during the study.

Age: 18Years +All GendersPhase 1
37 locations